Skip to main content

Table 1 Baseline characteristics of patients [Median (range)/n (%)]

From: A blinded-endpoint, randomized controlled trial of Sanyrene with natural active ingredient for prophylaxis of radiation dermatitis in patients receiving radiotherapy

Variables

Control intervention (n = 49)

Sanyrene (n = 50)

p

Median BMI(kg/m2)

23.0(17.8, 34.4)

23.9(16.2, 29.4)

0.499

Median Total dose (Gy)

50.0 (50.0, 72.6)

50.0 (16.0, 72.6)

0.327

BMI(kg/m2)

  

0.164

<18.5

1(2.0)

2(4.0)

 

18.5–23.9

29(59.2)

24(48.0)

 

24.0-27.9

13(26.5)

22(44.0)

 

≥28.0

6(12.2)

2(4.0)

 

Age (years)

  

0.270

≤50

26(53.1)

21(42.0)

 

>50

23(46.9)

29(58.0)

 

Sex

  

0.726

Male

16(32.7)

18(36.0)

 

Female

33(67.3)

32(64.0)

 

Smoke

  

0.248

No

49(100.0)

47(94.0)

 

Yes

0(0)

3(6.0)

 

Drink

  

0.986

No

47(95.9)

49(98.0)

 

Yes

2(4.1)

1(2.0)

 

ECOG

  

0.484

0

24(49.0)

28(56.0)

 

1

25(51.0)

22(44.0)

 

Tumor

  

0.761

Breast cancer

26(53.1)

25(50.0)

 

Head and neck cancer

23(46.9)

25(50.0)

 

Radiation Technique

  

0.757

3D-CRT

22(44.9)

24(48.0)

 

VMAT

27(55.1)

26(52.0)

 

CCRT

  

0.736

No

42(85.7)

44(88.0)

 

Yes

7(14.3)

6(12.0)

 
  1. BMI, body mass index; 3D-CRT, 3-dimensional conformal radiation therapy; VMAT, volumetric modulated arc radiation therapy; CCRT, concurrent chemotherapy